Our Vision

Become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

Our Mission

Better health for families worldwide.

Contents

Corporate

Directors

Executive Directors

- (陳啟宇)
- (姚方)
- (吳以芳)

Non-executive Directors

- (徐曉亮)
- (龔平)[1]
- (潘東輝)[1]
- (梁劍峰)[2]
- (王燦)[3]
- (沐海寧)[5]

Independent Non-executive Directors

- (江憲)

Stock Abbreviation

A A

Share Listing

A
C : 600196
C : 02196

A Share Registrar and Transfer Office in the PRC

C D & C C (DCC)
B
C B
166
D
, C

H Share Registrar and Transfer Office in Hong Kong

54, C
183

Company's Website

://www.

1 A 30 2020
2 17 2020
3 21 2020
4 A 21 2020
5 30 2020
6 A 30 2020

Financial

	Six months ended 30 June	
	2020	2019
	RMB million	[illegible]
Operating results		
	13,965	14,085
	7,749	8,486
[illegible]	**1,292**	1,490
[illegible]	**2,302**	2,196
[illegible]	**1,715**	1,516
B DA	**3,566**	3,483
Profitability		
[illegible]	**55.49%**	60.25%
[illegible]	**9.25%**	10.58%
[illegible]	**13.67%**	12.92%
Earnings per share [illegible]		

Management

D A

FINANCIAL REVIEW

D , :

D , 0.85% B13,965 2019.

D , B2,302 B1,715 , , 4.83% 13.10%, 2019. : (1) 2019- C ; (2) ( ), (B) (C) ; ( ) (2,000), B224 , B100 ; (3)

: (1) 2.6 ; (2) ; (3) ; (4) B .

D , 13.56% B0.67 2019.

REVENUE

D , 0.85% B13,965 2019. C B9,894 . B4,071 29.15%.

D , &D B9,952 , 7.97% 2019.

Management

SELLING AND DISTRIBUTION EXPENSES

R&D EXPENSES AND R&D EXPENDITURE

SHARE OF PROFITS OF ASSOCIATES

PROFIT FOR THE PERIOD

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

A ꞇ 30 2020, ꞇ ꞇ B23,358 m m B21,137 m ꞇ ꞇ 31 D m 2019 mꞇ

Maturity Structure of Outstanding Debts

: C : B

	30 June 2020	31 D 2019
1	12,405	8,560
1 2	7,834	6,860
2 5	2,633	5,396
5	483	321
	23,358	21,137

Available Facilities

A 30 2020, B9,750 , B32,709 . (B). A , B . A 30 2020, B48,320 , B15,611 .

Collateral and Pledged Assets

A 30 2020, : , B217 (31 D 2019: B134), B396 (31 D 2019: B303), B5 B4 .

D 16 .

Cash Flow

, , . ( ) , 2019.

: C : B

	January – June 2020	2019
	1,461	1,450
	(2,379)	(1,079)
	827	(496)
	(91)	(125)
C	8,284	7,175
C	8,177	7,052

Management
D A

D , 0.85% B13,965 2019. (&D) B9,952 , 7.97% 2019. B2,639 , 47.18% 2019. B1,359 , 6.85% 2019. &D B8,098 , 38.04% 9.96% 2019.

D , C B9,894 . B4,071 29.15%.

D , :

: C : B

Business segment	Revenue Jan – Jun 2020	2019	(%)
&D	**9,952**	10,814	7.97
	2,639	1,793	47.18
	1,359	1,459	6.85

D , B2,302 B1,715 , , 4.83% 13.10%, 2019. : (1) 2019- C , ; (2) ( ), (B) (C) , ; ( ) (2,000), B224 , B100 ; (3) , , , .

, : (1) 2.6 ; (2) ; (3) ; (4) B .

D , 2020 B1,461 , 0.77% 2019.

D , &D . &D B1,689 , 25.02% 2019. , &D B1,204 , B355 41.81% 2019.

Pharmaceutical Manufacturing and R&D

D [illegible] , [illegible] &D [illegible] B9,952 [illegible] 7.97% [illegible] 2019. [illegible] B1,116 [illegible] B1,115 [illegible] 7.40% [illegible] 9.54% [illegible] 2019, [illegible] &D [illegible] 27.92% [illegible] B1,541 [illegible] 15.4% [illegible] &D [illegible] B335 [illegible] 46.27% [illegible] 2019 [illegible] B1,059 [illegible] 10.6% [illegible]

[illegible] C D-19 [illegible] 2020, [illegible] 2019. [illegible] (B [illegible]) [illegible] C) [illegible] 61.9%, 109.6% [illegible] 244.5%, [illegible] . A [illegible] (2,000), [illegible] B224 [illegible] B100 [illegible]

[illegible]

: [illegible] C : B

Pharmaceutical manufacturing and R&D	Jan – Jun 2020	2019 (1)	(%)
[illegible] (2)	**1,767**	1,807	2.19
[illegible] (3)	**422**	264	59.94
[illegible] (4)	**1,800**	2,331	22.77
[illegible] (5)	**755**	1,224	38.35
[illegible] (6)	**1,248**	1,140	9.49
[illegible] (7)	**247**	419	41.03
[illegible] A [illegible]	**452**	675	32.97

1: [illegible] 2020 [illegible] (C [illegible]) [illegible] (A) [illegible]

2: [illegible] (A [illegible] A [illegible]), [illegible] (C) (B), [illegible]

3: [illegible]

4: [illegible] (C [illegible] C [illegible]), [illegible] D [illegible] (D), [illegible] (B), [illegible]

Management

D A

A &D

No.	Name of R&D project on drugs (products)	R&D stages as at the end of the Reporting Period in the PRC		R&D stages as at the end of the Reporting Period in other countries	
		R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	A -189 (C)	C			(.)
2	C -411	C			
3	-1501	C		C	(. A)
4	C -437	C		C	(.)
5		C			
6	C -159	C			
7	1001 (1)	C		C	(.)
8	D	C			
9	C -647 C	A			
10	C -207	A			
11	C -011 C	A			
12	C -338 (2)	A		A (.)	

1: D DA;

2: A C .

A &D

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	B		A (1)			
2	B	(2)				
3	B	A				
4	B	A - A	C	(3)		
5	B	A - / C A	A			

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period: R&D stage	R&D stages in China as at the end of the Reporting Period: Stage of clinical trial	R&D stages in other countries as at the end of the Reporting Period: R&D stage	R&D stages in other countries as at the end of the Reporting Period: Stage of clinical trial
6	B	A - 2 D A	A			
7	B	A - 2 D - A	C			
8	B	A -C A-4 A	A			
9	B	A - A A	A			
10	B	/ C A -CD20 A	C	(4)		
11	B	A - A	A			
12	B	A - 2 A (5)	C		A	
13	B	A - A (6)	C	/	A	
14	B	A -D-1 A	C (7)		A	
15	B	A -D- 1 A	A		C ( )	
16	B	22 A	C			
17	B	55 A	C			
18	B	56 A	A ( )			
19	C	C A -D-1 A A - A	C (10)			

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period: R&D stage	R&D stages in China as at the end of the Reporting Period: Stage of clinical trial	R&D stages in other countries as at the end of the Reporting Period: R&D stage	R&D stages in other countries as at the end of the Reporting Period: Stage of clinical trial
20	[illegible]	[illegible] D-1 [illegible]	[illegible]			
21	[illegible]	[illegible] D-1 [illegible] (C [illegible] + 5 [illegible]) [illegible]	[illegible]	[illegible]		
22	[illegible]	[illegible] D-1 [illegible]	[illegible]	[illegible]	[illegible]	[illegible]
23	[illegible]	[illegible] D-1 [illegible]	[illegible]	[illegible]		
24	[illegible]	[illegible] D-1 [illegible]	[illegible]	[illegible]	[illegible]	[illegible]
25	[illegible]	[illegible] D-1 [illegible]	[illegible]	[illegible]		

1: [illegible] 2020, [illegible] 2,000 [illegible], 2,000 [illegible] 500 [illegible] /50 [illegible] / [illegible] 2020, [illegible]

2: [illegible] 02 ([illegible] 汉曲优) [illegible]

Management

D A

3:

4:

5: A DA

6: A / DA

7: A B

: A A

:

10: D-1

A &D

No.	Type	Name of R&D project on drugs (products)	Indications	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
1	C	A-824	(D - B) (D - B) /	C	
2	C	A		C A	
3	C		C (1)	- D	
4	C	B			
5	C			C	
6	C				

No.	Type	Name of R&D project on drugs (products)	Indications	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
7 8	C [illegible]	[illegible] 002	[illegible]	[illegible] D A [illegible] A [illegible]	
9	[illegible]	C [illegible] D-19 [illegible] A [illegible] (B[illegible] 162 1)([illegible] 2)	[illegible] C [illegible] D-19		

1: A [illegible] A;

2: A [illegible], C [illegible] D-19 [illegible] A [illegible] (B[illegible] 162 1) [illegible] A [illegible] C [illegible]

[illegible] &D, [illegible] (CA[illegible]A) [illegible] D [illegible] D A [illegible]

A [illegible] C [illegible] 10 [illegible] A [illegible] ; 4 [illegible] A [illegible] B [illegible] 1 [illegible] 3 [illegible] ; 1 [illegible] DA; 1 [illegible] ; 1 [illegible] DA; [illegible] (D[illegible]) [illegible] (D[illegible]) [illegible] 02 [illegible] B [illegible]

Management

Medical Devices and Medical Diagnosis

Healthcare Services

D C D-19 2019. B1,359 6.85% 2019; B31 81.43% 2019, B2 98.40% 2019. C 3 4 37.8%

D A D Ba A, D C C C C 4,328

D

A B 11 A 2 D 5 C 3 C C C

Pharmaceutical Distribution and Retail

2020, B203,765 1.04% B4,803 B2,896 3.32% 2.67%

2020, 4.38% B157,495

Management

D A

Internal Integration and Operation Enhancement

Management
D[illegible] A[illegible]

A. Analysis on Principal Operations

(1) [illegible]

[illegible] C [illegible] B

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)	Reasons
[illegible]	**13,965**	14,085	0.85	
C[illegible]	**6,216**	5,599	11.02	
[illegible]	**3,931**	4,998	21.35	*1*
A[illegible]	**1,322**	1,148	15.16	
[illegible]	**1,204**	849	41.81	*2*
[illegible]	**428**	547	21.76	*3*
[illegible]	**1,461**	1,450	0.77	
[illegible]	**–2,379**	1,079	120.55	*4*
[illegible]	**827**	496	266.75	*5*

1: D [illegible] (A [illegible]) [illegible] ① [illegible] ② [illegible] ③ [illegible]

2: [illegible] &D [illegible]

3: [illegible]

4: [illegible]

5: [illegible]

(2) &

① &D

: C : B

&D	1,204
&D	485
&D	1,689
&D (%)	12.0
&D &D (%)	15.4
&D (%)	28.69

② D

D , &D &D B1,541 , B336 27.92% 2019, 15.4% &D . , ' &D , . A , &D , &D . A , &D . &D &D , , , .

B. Analysis of Segment and Regional Operations

(1)

[illegible] C [illegible] B

Principal operations by segments

By segments	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
[illegible] &D (1)	9,952	3,754	62.28	7.97	3.79	[illegible] 4.27 [illegible]
[illegible]	2,639	1,309	50.40	47.18	49.21	[illegible] 0.68 [illegible]
[illegible] (2)	1,359	1,130	16.82	6.85	4.68	[illegible] 9.16 [illegible]

Principal operations by products

Products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
[illegible] (3)	1,767	278	84.26	2.19	4.51	[illegible] 0.38 [illegible]
[illegible] (4)	422	119	71.89	59.94	71.10	[illegible] 1.83 [illegible]
[illegible] (5)	1,800	631	64.93	22.77	1.68	[illegible] 7.52 [illegible]
[illegible] (6)	755	48	93.63	38.35	16.94	[illegible] 1.64 [illegible]
[illegible] (7)	1,248	484	61.20	9.49	20.22	[illegible] 3.46 [illegible]
[illegible] ( )	247	20	91.74	41.03	0.42	[illegible] 3.37 [illegible]
[illegible]	452	330	27.11	32.97	31.29	[illegible] 1.79 [illegible]

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
C	9,894	4,093	58.63	8.30	11.40	7.32
	4,071	2,123	47.84	23.53	10.29	6.26

1: .63

C. Analysis of Major Subsidiaries and Investee Companies

(1) [illegible]

① [illegible]

[illegible] B

Name of subsidiary	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
[illegible]	[illegible] &D	[illegible]	197	5,753	3,514	2,414	485	416
[illegible]	[illegible] &D	[illegible]	440	5,176	2,770	2,825	441	369
[illegible]	[illegible] &D	[illegible]	N/A	6,956	5,645	1,476	562	419
[illegible]	[illegible] &D	[illegible]	510	2,626	1,864	599	64	61

[illegible]

② [illegible] B [illegible]

[illegible] B

Name of subsidiary	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Net profit
[illegible] (1)	[illegible] &D	[illegible]	543	5,536	3,708	110	448
[illegible] (2)	[illegible]	[illegible]	50	2,528	1,728	686	41
[illegible] (1)	[illegible] &D	[illegible]	N/A	2,745	2,302	504	40

1: [illegible] 2020 [illegible]

2: [illegible]

(2) 10%

Name of investee	Nature of business	Principal activities	Registered capital	Total assets	Net assets	Revenue	Operating profit
			100	307,273	84,008	203,765	4,808

(3)

① A

27 2020, 50% 100%

8 A 2020, 51% 100%

Name of subsidiary	Acquired through	Net assets (as at the end of Reporting Period)	Net profit (from date of acquisition/ merger up to the end of Reporting Period)	Date of acquisition/ merger
		47	25	19 2020
		4	6	9 2020

② D

29 2020, C

Name of subsidiary	Disposed through	Net assets as at date of disposal	Net profit from beginning of Reporting Period to date of disposal	Date of disposal
C	D		0	29 2020

D. Core Competitiveness Analysis

&D, &D,

&D,

E. Employees and Remuneration Policies

A 30,925

2. Business Outlook for the Second Half of 2020

2020, C D-19

2020, &D,

A 2020, C B C C

Pharmaceutical R&D and Manufacturing

Medical Devices and Medical Diagnosis

Healthcare Services

2020,

(D) (B).

C (重慶星榮整形醫院), C (徐州婦兒醫院),
C (上海星晨兒童醫院)

Pharmaceutical Distribution and Retail

2020,

Financing

2020,

3. Potential Risks

I. Risks in relation to industry policies and system reforms

C,

C

&D

II. Market risks

III. Business and operating risks

(1) &

(2) /

&D

(3)

IV. Management risks

(1)

(2)

V. Foreign exchange risk

VI. Force majeure risks

4. Other Events

A. 2019 Shareholding Increase Plan of the Controlling Shareholder

B. Inter-bank Market Debt Financing Instruments

C. Approval for Registration of Public Issuance of Corporate Bonds to Professional Investors

D. Proposed Overseas Listing of Gland Pharma

RESULTS AND DIVIDENDS

30 2020 41 77.

B

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Sell back of "17 Fosun 01" Corporate Bond

5 2020, C 1,580,500 17 01 17 01 C B ( ) 2017 ( ) C, .* (《上海復星醫藥(集團)股份有限公司2017年公開發行公司債券(面向合格投資者)(第一期)募集說明書》). 17 01 10,919,500 B100.

C C

DIRECTORS

A B D . D :

Executive Directors

. C (陳啟宇)

. (姚方)

. (吳以芳)

Non-executive Directors

. (徐曉亮)

. (龔平)

. D (潘東輝)

Independent Non-executive Directors

. (江憲)

D . (黃天祐)

. (李玲)

. (湯谷良)

17 2020, 21 2020, 30 2020, C D . A A 30 2020, D D B .

Statutory
D

SUPERVISORS

A

- (任倩)
- . C (曹根興)
- (管一民)

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

- . C D B : 01761), 30 2020.

- D C * (招金礦業股份有限公司) (: 01818), 24 A 2020.

- D * (上海證大房地產有限公司) (: 00755), 23 A 2020.

- D C ., .* (上海申通地鐵股份有限公司) (: 600834), 9 2020.

D . D C C * (長飛光纖光纜股份有限公司) (: 601869, 06869), 17 2020 B C ., .* (青島銀行股份有限公司) (: 002948, 03866), 13 2020.

- C * (上海華誼集團股份有限公司) (: 600623), 24 2020.

D (a) ( ) ( ) 13.51(2)

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

25 2019. () , ( ) , ( ) , ( )

170,444 1.1%

27 2019, 154,950 103 5,420 102 154,650 1%

17 2020, (1) (10) . A

D :

Participant	Date of Grant (dd-mm-yyyy)	Vesting Date (dd-mm-yyyy)[1]	Option share[1]	Exercise Period[1]		Outstanding options as at 1 January 2020	Adjusted during the Reporting Period[2]	Exercise price per share[3]	Forfeited or lapsed during the reporting period[4]	Outstanding options as at 30 June 2020
	27-6-2019	26-6-2020	40%	26-6-2020	26-6-2029	151,350	1,362,150	542	(20,000)	1,493,500
		31-3-2021		31-3-2021	26-6-2029					
		31-3-2022		31-3-2022	26-6-2029					
		31-3-2021	30%	31-3-2021	26-6-2029					
		31-3-2022		31-3-2022	26-6-2029					
		31-3-2022	30%	31-3-2022	26-6-2029					

:

(1)

(2) 17 2020.

(3) 17 2020.

(4) D , 3 20,000 .

(5) D , .

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

A a 30 2020, [illegible] D [illegible] D [illegible] C [illegible] C [illegible] C [illegible] D 2 a 3 [illegible] 5% [illegible] C [illegible]:

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares[1]	Approximate percentage of Shares in relevant class of Shares
[illegible]	[illegible]	[illegible]	48,803,000 ( )[2]	8.84%
[illegible]	[illegible]	[illegible]	938,095,290 ( )[2]	46.65%
[illegible]	[illegible]	[illegible]	48,803,000 ( )[2]	8.84%
[illegible]	[illegible]	[illegible]	938,095,290 ( )[2]	46.65%
[illegible]	[illegible]	[illegible]	48,803,000 ( )[2]	8.84%
[illegible]	[illegible]	[illegible]	938,095,290 ( )[2]	46.65%
[illegible]	[illegible]	[illegible]	48,803,000 ( )[2]	8.84%
[illegible]	[illegible]	[illegible]	938,095,290 ( )[2]	46.65%
[illegible]	[illegible]	[illegible]	48,803,000 ( )[2]	8.84%
	[illegible]	[illegible]	938,095,290 ( )[2]	46.65%
	[illegible]	[illegible]	114,075 ( )	0.01%
[illegible]	[illegible]	[illegible]	38,723,000 ( )	7.02%
[illegible] & C.	[illegible]	[illegible]	38,707,016 ( )	7.01%
[illegible]	[illegible]	[illegible]	28,195,990 ( )	5.11%
			782,000 ( )	0.14%

:

(1) ( ) [illegible]

(2) [illegible] 71.09% [illegible] 85.29% [illegible]

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

D [illegible] C [illegible] D [illegible] C [illegible] D [illegible] C [illegible].

Statutory
D

MODEL CODE FOR SECURITIES TRANSACTIONS

COMPLIANCE WITH THE CG CODE

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

21 2020,

30 2020,

30 2020.

Chen Qiyu

25 A 2020

Interim Condensed Consolidated

For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020	2019
		RMB’000	B’000
		(Unaudited)	( )
REVENUE	5	**13,965,179**	14,085,146
C		**(6,215,872)**	(5,598,983)
		7,749,307	8,486,163
	6	**180,429**	109,724
		(3,931,067)	(4,998,448)
A		**(1,322,239)**	(1,147,889)
		(1,204,425)	(849,383)
		(42,765)	(21,918)
	7	**603,622**	389,686
		(52,138)	(45,617)
		96,436	86,650
	8	**(427,878)**	(546,940)
:			
		(46,558)	(25,933)
A		**698,964**	760,055
PROFIT BEFORE TAX	9	**2,301,688**	2,196,150
	10	**(392,081)**	(376,521)
PROFIT FOR THE PERIOD		**1,909,607**	1,819,629
A :			
		1,714,710	1,516,120
-		**194,897**	303,509
		1,909,607	1,819,629
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
B		**RMB0.67 Yuan**	B0.59
D		**RMB0.67 Yuan**	B0.59

Interim Condensed Consolidated
[illegible]

[illegible] 30 [illegible] 2020

	For the six months ended 30 June	
	2020	2019
	RMB'000	[illegible]B'000
	(Unaudited)	([illegible])
PROFIT FOR THE PERIOD	**1,909,607**	1,819,629
OTHER COMPREHENSIVE (LOSS)/INCOME		
[illegible]:		
[illegible]	**(255,609)**	100,825
[illegible]	**27,958**	(30,026)
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	**(227,651)**	70,799
[illegible]:		
[illegible]		
[illegible]	**3,727**	(26,819)
[illegible]	**24**	(5)
	3,751	(26,824)
[illegible]	**68,933**	
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	**72,684**	(26,824)
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	**(154,967)**	43,975
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**1,754,640**	1,863,604
A[illegible]:		
[illegible]	**1,660,547**	1,544,923
[illegible]	**94,093**	318,681
	1,754,640	1,863,604

Interim Condensed Consolidated

30 June 2020

	Notes	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
NON-CURRENT ASSETS			
	13	11,313,846	10,720,960
		2,389,837	2,454,742
		9,093,050	9,013,990
		9,238,300	9,036,246
		356,204	381,332
		21,712,444	20,491,557
		60,945	107,709
		1,851,891	1,983,155
D		236,457	196,095
		1,300,703	1,273,605
		57,553,677	55,659,391
CURRENT ASSETS			
		4,561,539	3,940,537
	14	5,271,488	4,607,722
		1,628,029	1,420,087
		992,812	456,651
D		354,915	445,103
C		9,750,416	9,533,268
		22,559,199	20,403,368
CURRENT LIABILITIES			
	15	2,864,017	2,397,315
		6,116,649	5,376,193
	16	12,404,601	8,560,202
		138,571	143,786
C		527,652	503,683
		487,052	452,587
		22,538,542	17,433,766
NET CURRENT ASSETS		20,657	2,969,602
TOTAL ASSETS LESS CURRENT LIABILITIES		57,574,334	58,628,993

30 2020

	Notes	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
NON-CURRENT LIABILITIES			
-	16	**10,953,518**	12,576,907
		369,340	410,188
D		**2,928,227**	2,994,048
D		**417,091**	417,345
-		**2,891,682**	2,860,170
C		**215,655**	223,009
-		**17,775,513**	19,481,667
Net assets		**39,798,821**	39,147,326
EQUITY			
Equity attributable to owners of the parent			
		2,562,899	2,562,899
		30,419,792	29,268,280
		32,982,691	31,831,179
Non-controlling interests		**6,816,130**	7,316,147
Total equity		**39,798,821**	39,147,326

Chen Qiyu **Wu Yifang**

Interim Condensed Consolidated
[illegible]

For the six months ended 30 June 2020

	Attributable to owners of the parent									
	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
[illegible] 2020 [illegible]	2,562,899	11,385,162*	(35,546)*	2,523,799*	899,356*	(420,878)*	14,916,387*	31,831,179	7,316,147	39,147,326
[illegible]	—	—	—	—	—	—	1,714,710	1,714,710	194,897	1,909,607
[illegible]	—	—	3,819	—	—	—	—	3,819	(68)	3,751
[illegible]	—	—	96,891	—	—	—	—	96,891	—	96,891
[illegible]	—	—	—	—	—	(154,873)	—	(154,873)	(100,736)	(255,609)
[illegible]	—	—	100,710	—	—	(154,873)	1,714,710	1,660,547	94,093	1,754,640
[illegible]	—	—	—	—	159,607	—	—	159,607	(521,291)	(361,684)
[illegible]	—	—	—	—	(784)	—	—	(784)	62	(722)
[illegible]	—	—	—	—	(2,433)	—	—	(2,433)	—	(2,433)
[illegible]	—	—	—	—	—	—	—	—	56	56
[illegible]	—	—	—	—	—	—	—	—	24,495	24,495
[illegible]	—	—	—	—	—	—	—	—	(241,721)	(241,721)
[illegible]	—	—	—	—	—	—	—	—	162,645	162,645
[illegible]	—	—	—	—	5,346	—	—	5,346	(18,356)	(13,010)
[illegible]	—	—	—	—	329,734	—	—	329,734	—	329,734
[illegible] 2019 [illegible] (11)	—	—	—	—	—	—	(1,000,505)	(1,000,505)	—	(1,000,505)
[illegible]	—	—	107,320	—	—	—	(107,320)	—	—	—
[illegible] 30 [illegible] 2020 [illegible]	2,562,899	11,385,162*	172,484*	2,523,799*	1,390,826*	(575,751)*	15,523,272*	32,982,691	6,816,130	39,798,821

* [illegible] RMB30,419,792,000 (31 D[illegible] 2019: RMB29,268,280,000) [illegible]

Interim Condensed Consolidated

30 2020

	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000
A 1 2019 (A)	2,563,061	11,386,711*	(1,711)	30,105*	2,374,998*	(701,196)*	(293,315)*	12,562,197*	27,920,850	5,614,977	33,535,827
								1,516,120	1,516,120	303,509	1,819,629
C				(26,838)					(26,838)	14	(26,824)
				(30,026)					(30,026)		(30,026)
							85,667		85,667	15,158	100,825
				(56,864)			85,667	1,516,120	1,544,923	318,681	1,863,604
A						(81,915)			(81,915)	(9,499)	(91,414)
C A	(162)	(1,549)	1,711								
A										23,284	23,284
D						1,129			1,129	(1,129)	
D						(2,214)			(2,214)		(2,214)
D					(1,000)			1,000			
C					(314)			314		(662)	(662)
C										31,290	31,290
D										(170,553)	(170,553)
A										61,867	61,867
						39,361			39,361	(86,121)	(46,760)
						67,968			67,968	6,876	74,844
2018								(818,627)	(818,627)		(818,627)
A 30 2019 ( )	2,562,899	11,385,162*		(26,759)*	2,373,684*	(676,867)*	(207,648)*	13,261,004*	28,671,475	5,789,011	34,460,486

* B26,108,576,000 (31 D 2018: B25,359,500,000)

Interim Condensed Consolidated [illegible]

For the six months ended 30 June 2020

	Notes	For the six months ended 30 June 2020 RMB'000 (Unaudited)	2019 [illegible]B'000 ([illegible])
[illegible]		**1,928,625**	1,849,335
[illegible]		**(467,328)**	(399,147)
[illegible]		**1,461,297**	1,450,188
CASH FLOWS FROM INVESTING ACTIVITIES			
[illegible]		**(1,904,148)**	(2,040,985)
[illegible]	17	**(8,400)**	(133,162)
[illegible]		**(192,431)**	(174,524)
[illegible]		**(435,607)**	(109,283)
[illegible]		**151,917**	35,418
[illegible]		**474,449**	642,245
[illegible]		**—**	2,296
[illegible]		**67,961**	41,866
[illegible]		**—**	1,039
[illegible]		**18,718**	20,053
[illegible]		**1,708**	
[illegible]		**5,439**	26,015
[illegible]		**50,228**	
[illegible]		**(570,138)**	570,562
[illegible]		**(38,629)**	39,801
[illegible]		**(2,378,933)**	(1,078,659)

Interim Condensed Consolidated

30 2020

Notes to Interim Condensed Consolidated

30 June 2020

1. CORPORATE AND GROUP INFORMATION

2. BASIS OF PREPARATION

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

(a) ... 3 ... 1 ... 2020.

( ) ... 9, ... 39 ... 7 ...

( ) ... 16 ... -19 ... -19 ... 30 2021; ... 1 2020 ...

D ... 30 2020, ... -19 ... 1 ... 2020 ... -19 ... 30 2020. ... B4,787,000.00 ... 30 2020.

( ) ... 1 ... 8 ...

4. OPERATING SEGMENT INFORMATION

(a) &D

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	Pharmaceutical manufacturing and R&D RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Adjustments and Eliminations RMB'000	Total RMB'000
Segment revenue:							
	9,952,096	2,638,887	1,359,017	—	15,179	—	13,965,179
	48,294	46,610	4,700	—	8,270	(107,874)	—
	10,000,390	2,685,497	1,363,717	—	23,449	(107,874)	13,965,179
Segment results*	1,115,513	509,746	31,373	—	(4,289)	(19,026)	1,633,317
	135,673	10,551	16,910	—	16,579	—	179,713
	157,704	14,210	3,393	—	275,233	30	450,570
	56,129	10,345	17,531	—	185	(5,291)	78,899
	(51,353)	(14,125)	(17,409)	—	(5,587)	26,170	(62,304)
	27,605	(55,433)	(6,267)	—	(22,062)	—	(56,157)
	(45,744)	—	—	—	(814)	—	(46,558)
A	32,681	24,021	(31,134)	724,041	(50,645)	—	698,964
							171,305
							(365,574)
							(380,487)
	1,428,208	499,315	14,397	724,041	208,600	1,883	2,301,688
	(313,433)	(65,625)	(12,784)	—	(239)	—	(392,081)
	1,114,775	433,690	1,613	724,041	208,361	1,883	1,909,607
Segment assets:	41,047,332	8,262,367	9,812,781	13,877,770	4,251,314	(1,683,155)	75,568,409
	349,474	—	—	—	6,730	—	356,204
	2,248,581	1,102,609	1,624,283	13,877,770	2,859,201	—	21,712,444
							4,544,467
							80,112,876
Segment liabilities:	18,654,179	1,937,780	2,229,824	—	386,141	(9,370,028)	13,837,896
							26,476,159
							40,314,055
Other segment information:							
D	590,999	96,170	133,901	—	15,197	—	836,267
	(32,251)	49,686	2,365	—	22,048	—	41,848
C **	1,309,447	97,984	356,886	—	47,953	—	1,812,270

*

**

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2019 (unaudited)

	&D B'000	B'000	B'000	B'000	B'000	B'000	B'000
Segment revenue:							
	10,814,123	1,792,865	1,458,512		19,646		14,085,146
	8,421	19,401	1,876		20,674	(50,372)	
	10,822,544	1,812,266	1,460,388		40,320	(50,372)	14,085,146
Segment results*	1,204,721	291,795	168,982		10,328	(19,887)	1,655,939
	75,540	13,034	3,681		3,326		95,581
	281,499	(3,481)	(748)	7,274	2,679		287,223
	50,628	16,153	21,874		216	(1,236)	87,635
	(56,712)	(9,467)	(12,032)		(6,320)	29,102	(55,429)
	(15,616)	(22,095)	(15,446)		1,121		(52,036)
	(25,565)	477			(845)		(25,933)
A	37,529	(25,330)	(13,655)	774,939	(13,428)		760,055
							115,621
							(491,511)
							(180,995)
	1,552,024	261,086	152,656	782,213	(2,923)	7,979	2,196,150
	(319,655)	(30,673)	(51,774)		(258)		(402,360)
							25,839
	1,232,369	230,413	100,882	782,213	(3,181)	7,979	1,819,629
Segment assets:	36,425,494	6,874,258	10,781,464	12,429,996	4,362,843	(1,490,584)	69,383,471
	399,018	12,808			9,134		420,960
	2,153,707	948,143	3,232,275	12,429,996	3,085,411		21,849,532
							4,249,250
							73,632,721
Segment liabilities:	15,346,659	1,505,277	1,698,142		281,002	(8,590,276)	10,240,804
							28,931,431
							39,172,235
Other segment information:							
D	502,504	85,220	133,338		19,190		740,252
	2,435	19,425	6,493		(2,198)		26,155
C**	1,016,436	85,165	160,766		95,489		1,357,856

[redacted]densed Consolidated

[redacted]	[redacted] mont[redacted]s ended 30 June	
	[redacted]2020	2019
	[redacted]'000	B'000
	[redacted]ted)	( )
[redacted]	[redacted],418	14,066,560
[redacted]	[redacted],761	18,586
[redacted]	[redacted],179	14,085,146

[redacted]ormation for revenue from contrac[redacted]

2020 ( )

5. REVENUE (Continued)

For the six months ended 30 June 2019 (unaudited)

[illegible]	&D B'000	B'000	B'000	B'000	B'000
Types of goods or services					
[illegible]	10,564,090	1,671,542	27,181		12,262,813
	238,771	111,402	1,430,327	2,144	1,782,644
[illegible]	11,182	9,921			21,103
[illegible]	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Geographical markets					
[illegible]	8,288,825	1,024,242	1,457,508	406	10,770,981
[illegible]	2,525,218	768,623		1,738	3,295,579
[illegible]	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Timing of revenue recognition					
[illegible]	10,575,272	1,681,463	27,181		12,283,916
[illegible]	128,209	41,595	1,430,327	2,144	1,602,275
[illegible]	110,562	69,807			180,369
[illegible]	10,814,043	1,792,865	1,457,508	2,144	14,066,560

6. OTHER INCOME

	For the six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	( )
D	**20,391**	17,523
	158,367	92,104
	1,671	97
	180,429	109,724

7. OTHER GAINS

	For the six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	( )
	87,209	27,528
	439,102	327,405
	—	2,186
	77,311	32,567
	603,622	389,686

8. FINANCE COSTS

	For the six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	( )
( )	**425,687**	543,161
	12,188	12,355
:	**(9,997)**	(8,576)
	427,878	546,940

9. PROFIT BEFORE TAX

[illegible]:

	For the six months ended 30 June	
	2020	2019
	RMB'000	[illegible]B'000
	(Unaudited)	([illegible])
C[illegible]	**4,932,900**	4,263,438
C[illegible]	**1,282,972**	1,335,545
[illegible]		
[illegible]	**2,468,297**	1,952,209
[illegible]:		
D[illegible]	**66,453**	134,290
A[illegible]:		
D[illegible]	**83,795**	67,904
[illegible]	**39,516**	46,956
	2,658,061	2,201,359
[illegible]:		
C[illegible]	**1,167,594**	816,188
[illegible] &D [illegible]*	**46,028**	12,128
	1,121,566	804,060
[illegible]	**12,963**	10,981
D[illegible]	**490,945**	458,599
D[illegible]	**91,076**	74,916
A[illegible]	**254,247**	206,737
([illegible])/[illegible]	**(917)**	4,237
[illegible]	**42,765**	21,918
[illegible]	**(439,102)**	(327,405)
[illegible]	**(69,551)**	(6,028)
[illegible]	**(1,621)**	(18,465)

* [illegible]

10. INCOME TAX

C 25% (30 2019: 25%) C C 1 2008, C 0% 20%.

16.5% A ., C , 9.48%. ( ), C , 34.94% 1 A 2018 31 2019 25.17% 31 2019. B AB (B), C , 22%. .AS ( ), C , 33.33%.

30 2020 2019 :

	For the six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	( )
C	**467,327**	464,045
D	**(75,246)**	(87,524)
	392,081	376,521

11. DIVIDENDS

D 30 2020 (30 2019:).

B0.39 ( ) 31 D 2019 C 30 2020.

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

13. PROPERTY, PLANT AND EQUIPMENT

	B'000 ( )
C 1 2020	10,720,960
A	1,191,624
A	14,953
D	(77,353)
D	(490,945)
	(45,393)
C 30 2020	11,313,846

, B217,305,000 (31 D 2019: B133,709,000), - 16 .

14. TRADE AND BILLS RECEIVABLES

	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
	5,080,545	4,367,600
B	**190,943**	240,122
	5,271,488	4,607,722

, . - - .

14. TRADE AND BILLS RECEIVABLES (Continued)

A

	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
1	4,999,855	4,302,722
2	144,630	111,346
2 3	67,601	61,584
3	125,446	114,549
	5,337,532	4,590,201
:	(256,987)	(222,601)
	5,080,545	4,367,600

A 30 2020, B5,300,000 (2019: B8,146,000)

15. TRADE AND BILLS PAYABLES

	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
	2,566,965	2,152,747
B	297,052	244,568
	2,864,017	2,397,315

A :

	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
1	2,516,937	2,105,194
2	34,054	36,473
2 3	9,155	3,082
3	6,819	7,998
	2,566,965	2,152,747

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

		30 June 2020 RMB'000 (Unaudited)	31 D[illegible] 2019 [illegible]B'000 (A[illegible])
Ba[illegible] :	*(1)*		
[illegible]		486,008	344,186
[illegible]		15,096,396	13,762,714
		15,582,404	14,106,900
[illegible]	*(2)*	899,616	
C[illegible]	*(3)*	6,876,099	7,030,209
[illegible]		23,358,119	21,137,109
[illegible]		(12,404,601)	(8,560,202)
[illegible]		10,953,518	12,576,907

A[illegible] :

	30 June 2020 RMB'000 (Unaudited)	31 D[illegible] 2019 [illegible]B'000 (A[illegible])
[illegible] :		
[illegible] 1 [illegible]	12,404,601	8,560,202
[illegible] 1 [illegible] 2 [illegible]	7,833,867	6,860,077
2 [illegible] 5 [illegible]	2,633,443	5,395,435
[illegible] 5 [illegible]	486,208	321,395
	23,358,119	21,137,109
[illegible]	(12,404,601)	(8,560,202)
[illegible]	10,953,518	12,576,907

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

(1) Bank loans

0.3000% 6.2000% (31 D 2019: 0.7500% 7.5000%).

A 30 2020, (13) B217,305,000 (31 D 2019: B133,709,000), B396,459,000 (31 D 2019: B303,453,000).

A 30 2020, B5,300,000 (31 D 2019: B8,146,000) B4,376,000 (31 D 2019:).

(2) Super Short-term Commercial Paper

2 2020, C B600,000,000, 2.50% . C 27 2020.

8 A 2020, C B300,000,000, 2.20% . C 7 2020.

(3) Corporate bonds

4 2016, C B3,000,000,000, 3.35% . 4 2021. 4 2019, B5,500,000 C , 4 2021. 4.50%.

14 2017, C B1,250,000,000, 4.50% . 14 2022. 14 2020, B158,050,000 C , 14 2022. 3.48%.

13 A 2018, C B1,300,000,000, 5.10% . 13 A 2023.

30 2018, C B500,000,000 B1,000,000,000, 4.47% 4.68% . 30 2022. 30 2023.

17. BUSINESS COMBINATION

19 [illegible] 2020, [illegible] 50% [illegible] B10,900,000. [illegible] 100% [illegible]

9 [illegible] 2020, [illegible] 51% [illegible] B5,250,000. [illegible] 100% [illegible]

[illegible]:

	Notes	Fair value recognised on acquisition B'000 ([illegible])
[illegible]	13	14,953
[illegible]		518
[illegible]		33,774
[illegible]		11,142
[illegible]		40,494
[illegible]		14,529
[illegible]		(12,132)
[illegible]		(405)
[illegible]		(70,779)
[illegible]		32,094
[illegible]		(15,944)
		16,150
[illegible]:		
[illegible]		16,150

[illegible] B40,494,000 [illegible] B9,524,000, [illegible].

17. BUSINESS COMBINATION (Continued)

A [illegible]:

	B'000 ([illegible])
C[illegible]	(10,970)
C[illegible]	14,529
	3,559
[illegible] 31 D[illegible] 2019	(11,959)
	(8,400)

18. COMMITMENTS

[illegible]:

	30 June 2020 RMB'000 (Unaudited)	31 D[illegible] 2019 B'000 (A[illegible])
C[illegible]:		
[illegible]	2,316,640	2,191,767
[illegible]	880,140	929,930
[illegible]	253,149	273,236
A[illegible]:		
[illegible]	4,434,832	4,285,335
	7,884,761	7,680,268

19. RELATED PARTY TRANSACTIONS

[illegible]:

(a) Sales of pharmaceutical products and services

	For the six months ended 30 June 2020 RMB'000 (Unaudited)	2019 [illegible]B'000 ([illegible])
[illegible] (4 & 6 & 15)	1,395,932	1,567,956
[illegible] (1 & 4 & 16)	188,335	205,246
[illegible] (3 & 4 & 10 & 16)	98,576	216
[illegible] (1 & 4)	92,686	49,757
[illegible] (1 & 4)	68,855	42,836
[illegible] (4 &)	7,036	32,492
[illegible] (4 &)	4,315	
[illegible] (1 & 4)	4,030	3,256
[illegible] (1 & 4)	2,555	1,453
[illegible] (1 & 4)	1,777	22
[illegible] (2 & 4 & 17)	1,612	4,702
[illegible] (1 & 4)	1,262	
[illegible] (1 & 4 & 6)	737	1,575
[illegible] (2 & 4)	406	148
[illegible] (4 &)	42	
[illegible] (4 &)	16	
[illegible] (4 & 7)	16	17
[illegible] (2 & 4)	14	12
[illegible] (1 & 4)	13	60
[illegible] (1 & 4)	3	
[illegible] (1 & 4)	—	17
[illegible] (1 & 4)	—	1
	1,868,218	1,909,766

19. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	([illegible])
[illegible] C ., . [illegible] (4 & 6 & 15)	**128,644**	125,937
[illegible] (3 & 4 & 11 & 16)	**96,578**	1,156
[illegible] C [illegible] . (4 &)	**87,769**	8,899
C. [illegible] C ., . [illegible] (1 & 4 & 16)	**2,266**	410
[illegible] A [illegible] & C ., . (1 & 4)	**1,071**	1,164
A [illegible] C ., . (1 & 4)	**1,007**	2,126
[illegible] D [illegible] C ., . (2 & 4 & 17)	**907**	85
[illegible] D'[illegible] D [illegible] C ., . [illegible] (4 &)	**510**	3,352
[illegible] ., . (4 &)	**33**	
[illegible] C ., . (1 & 4)	**23**	
[illegible] B [illegible] ., . (1 & 4)	**—**	1,318
C [illegible] C [illegible]) [illegible] C ., . (1 & 4 & 1)	**—**	1,228
	318,808	145,675

(c) Leasing and property management services

As lessor	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	([illegible])
[illegible] B [illegible] C ., . (2 & 5)	**6,106**	5,310
[illegible] (3 & 5 & 12 & 16)	**3,529**	7,895
[illegible] C ., . (1 & 5)	**733**	
[illegible] D [illegible] C ., . (2 & 5 & 17)	**578**	325
D [illegible]) C ., . (5 & 7)	**471**	454
[illegible] C [illegible] (1 & 5 & 6)	**413**	131
[illegible] D [illegible] . (2 & 5)	**216**	
[illegible]) C ., . (1 & 5)	**145**	86
[illegible] C ' [illegible] (1 & 5)	**65**	
[illegible] C ., . (1 & 5)	**—**	264
	12,256	14,465

19. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 B'000 ( )
(3 & 5 & 13 & 16)	2,952	5,477
D (5 &)	117	114
(5 &)	43	41
B C ., (5 &)	—	2,500
	3,112	8,132

Property management services	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 B'000 ( )
(3 & 5 & 14 & 16)	6,904	6,651

(d) Loans from/to a related parties

C C ( ), C , , , C B C 1 2020 31 D 2022. B1,000,000,000. B1,000,000,000.

Maximum daily outstanding balance of deposits in Fosun Finance	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 B'000 ( )
C (& 16)	979,619	574,422

19. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

A loan from a related party	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
C (& 16)	52,274	38,779

C , ( ) ' ( ) - B10,884,000 3%.

D C ., . - B188,840,000 10% .

Loans to related parties	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A)
' ( ) (1 & 16)	10,884	10,566
B C ., . (2 & 16)	188,840	188,840
	199,724	199,406

(e) Interest income from/to related parties

Interest income	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 B'000 ( )
B C ., . (2 & 16)	4,706	2,002
C (& 16)	3,358	1,845
' ( ) (1 & 16)	160	154
	8,224	4,001

19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)

10% 3%.

Interest expense	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019
(& 16)	1,058	1,619

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)

(C)

(14) D , C ., . B C ., .

(15) C ., .

(16) C 14A . C 14A .

(17) D C ., . 19 2020.

(18) C C) C ., . 9 2020.

(f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	( )
	50,051	25,416
	15,410	12,417
	243	501
	65,704	38,334

(g) Outstanding balances with related parties

( ) A 30 2020, B51,513,000 (31 D 2019: B4,030,000) . , - .

( ) A 30 2020, B983,814,000 (31 D 2019: B1,071,384,000) . , - .

( ) A 30 2020, B193,654,000 (31 D 2019: B212,705,000) , - .

( ) A 30 2020, B3,942,000 (31 D 2019: B5,526,000) , - .

( ) A 30 2020, B118,211,000 (31 D 2019: B46,027,000) . , - .

19. RELATED PARTY TRANSACTIONS (Continued)

(g) Outstanding balances with related parties (Continued)

( ) A 30 2020, B81,705,000

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 assets

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities (Continued)

[illegible] B2,643,984,000 (31 D [illegible] 2019: B2,818,244,000) B DA ([illegible] B [illegible], [illegible], D [illegible] A [illegible]) [illegible] 2018, [illegible] B DA [illegible] 2019.

Fair value hierarchy

[illegible]:

Assets measured at fair value:

30 [illegible] 2020 ([illegible])

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
[illegible]	566	849	59,530	60,945
[illegible]	1,097,737	52,959	1,694,007	2,844,703
D [illegible]	—	354,915	—	354,915
	1,098,303	408,723	1,753,537	3,260,563

31 [illegible] 201[illegible] ([illegible])

	[illegible]			
	[illegible] (1) B'000	[illegible] (2) B'000	[illegible] (3) B'000	[illegible] B'000
[illegible]	1,554	52,909	53,246	107,709
[illegible]	561,348	52,734	1,825,724	2,439,806
D [illegible]		445,103		445,103
	562,902	550,746	1,878,970	2,992,618

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

3 :

30 2020

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
A 1 2020	**1,825,724**	**53,246**
	118,774	**—**
	—	**6,284**
A	**68,397**	**—**
D	**(321,675)**	**—**
	2,787	**—**
A 30 2020	**1,694,007**	**59,530**

3 :

30 201

	B'000 ( )	D B'000 ( )
A 1 2019	2,155,293	82,301
	231,452	
		(29,271)
A	116,220	
D	(332,911)	
	3,116	(340)
2	(386,601)	
A 30 2019	1,786,569	52,690

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

30 2020 ( )

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
A	**—**	**—**	**2,643,984**	**2,643,984**

31 201 ( )

	(1) B'000	(2) B'000	(3) B'000	B'000
A			209,286	209,286
A			2,608,958	2,608,958
			2,818,244	2,818,244

3 :

	Six months ended 30 June	
	2020 **RMB'000** **(Unaudited)**	2019 B'000 ( )
A 1	**2,818,244**	2,913,876
A	**35,026**	46,708
D	**(209,286)**	
A 30	**2,643,984**	2,960,584

D , 1 2(30 2019:).

21. CONTINGENT LIABILITIES

A 30 2020 31 D 2019, .

22. EVENTS AFTER THE REPORTING PERIOD

A , .

23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

D 25 A 2020.

( )	( ) C B1.00 B
( )	( )
A	C
A A A	C
A	A C ., .* (錦州奧鴻藥業有限責任公司), C
A	C A
B	D
B	B
B	B AB, C
B	B
CA A	C A & A
C C	C C C A 14
	C
C	C C C * (佛山市禪城區中心醫院有限公司), - D A C D , (佛山市禪城區人口和衛生藥品監督管理局), C
C	C C * (佛山市禪怡健康管理有限公司)
C C (B)	C C D (B) C ., .* (希米科醫藥技術發展(北京)有限公司)
C C	C C ( ) C ., .* (希米科(蘇州)醫藥科技有限公司) (A ( ) C ., .* (復星艾迪(蘇州)醫藥科技有限公司)), C
C	( ) C ., .* (上海復星醫藥(集團)股份有限公司), C A B
( )	C .

* (中國證券監督管理委員會),

* (上海復星高科技(集團)有限公司),

14A.07(1)

(復星控股有限公司),

(復星國際有限公司),

: 00656)

(復星國際控股有限公司), 85.29%

Definitions

* (岳陽廣濟醫院有限公司),

* (桂林南藥股份有限公司),

B1.00

* (深圳恒生醫院),

.* (淮安興淮國際醫院有限公司),

* (直觀復星醫療器械技術(上海)有限公司) .* (直觀復星(香港)有限公司)

* (安徽濟民腫瘤醫院), (民辦非企業單位)

10

* (中華人民共和國國家藥品監督管理局),

[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
[illegible]	[illegible]
&D	[illegible]
[illegible]	6-[illegible] 1 [illegible] 2020 30 2020
B	[illegible]
[illegible]	[illegible]
[illegible]	(C [illegible] 571 [illegible])
[illegible]	B [illegible] .* (上海復宏漢霖生物技術股份有限公司), [illegible] : 02696) [illegible]
[illegible] B [illegible]	B [illegible] C ., .* (上海復宏漢霖生物製藥有限公司), [illegible]
[illegible]	[illegible] * (《上海證券交易所股票上市規則》)
[illegible]	[illegible] * (上海證券交易所)
[illegible]	D [illegible] C ., .* (上海星耀醫學科技發展有限公司), [illegible]
[illegible]	[illegible]
[illegible]	[illegible] B1.00 [illegible] A [illegible]
[illegible]	[illegible] * (深圳證券交易所)
[illegible]	C . .* (國藥控股股份有限公司), [illegible] ([illegible] : 01099)
[illegible]	C ., .* (國藥產業投資有限公司)
[illegible]	[illegible] : 01696) [illegible]
[illegible] ( )	[illegible]
[illegible]	[illegible]

Definitions

C	C C
/ C	C .,* (宿遷市鐘吾醫院有限責任公司) C * (宿遷市腫瘤醫院), C
	* (宿遷市新星康復體檢有限公司), C
.	A , D C
, D $	
DA	. D A
	B C * (江蘇萬邦生化醫藥集團有限責任公司), C
	C * (溫州老年病醫院有限公司), C
	C .,* (武漢濟和醫院有限公司), C
C	C D / C * (《董事／有關僱員進行證券交易的書面指引》)
	C C * (重慶藥友製藥有限責任公司), C
C	C * (珠海禪誠醫院有限公司), C
%	
, C	C , C , , , C .